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Key Points
• At CML diagnosis, ad-
ditional chromosomal
lesions beyond the Ph
translocation confer
a higher risk of later
disease progression.
• The adverse effect of
these lesions is inde-
pendent of the widely
used Sokal and ELTS
risk scores.
At diagnosis of chronic-phase chronic myeloid leukemia (CML), there are conflicting data as
to whether additional cytogenetic abnormalities (ACAs) beyond a standard Philadelphia (Ph)
translocation confer a higher risk of subsequent disease progression. In the United Kingdom
SPIRIT2 trial comparing imatinib 400 mg daily with dasatinib 100 mg daily, diagnostic
karyotypes were available in 763 of the 814 patients recruited. Of these, 27 had ACAs in
either/both the original 4 major route group (trisomy 8 or 19, iso17q or a second Ph) or the 5
additional lesions recently described (trisomy 21, 3q26.2, monosomy 7/7q2, 11q23, and
complex karyotypes), and their progression rate was significantly higher (22.2%) than in
patients without one of these ACAs (2.2%; P , .001). Patients with ACAs had worse
progression-free survival (PFS; hazard ratio [HR], 5.21; 95% confidence interval [CI], 2.59-
10.50; P , .001) and freedom from progression (FFP; HR, 12.66; 95% CI, 4.95-32.37; P , .001)
compared with patients without ACAs. No association was seen between the Sokal or
European Treatment and Outcome Study long-term survival (ELTS) scores and the presence
of ACAs. Univariate analysis showed that higher Sokal and ELTS scores and the presence of
ACAs were associated with poorer PFS, though only ACAs and high-risk ELTS scores were
associated with poorer FFP. Multivariable models identified both the Sokal/ELTS score and
ACAs as significant independent factors for PFS but only ELTS score and ACAs as significant
independent factors for FFP. The data support the view that certain ACAs are predictive of
disease progression independently of Sokal or ELTS scores.
Introduction
In chronic myeloid leukemia (CML), disease progression to blast crisis may be accompanied by
additional cytogenetic abnormalities (ACAs) beyond the standard t(9;22) Philadelphia (Ph)
translocation. The most common new lesions include trisomy 8, an additional Ph translocation,
isochromosome 17q, and trisomy 19.1-3 However, the prognostic significance at chronic phase
diagnosis of these 4 “major route” lesions for disease progression is less clear. Although emerging
clones may be transient and not associated with disease progression,4 early reports correlate the
appearance of ACAs with clinical deterioration,5 and patients with ACAs present at diagnosis had
a shorter survival.6
Since the advent of tyrosine kinase inhibitor (TKI) therapy, progression is much less common, and the
significance of ACAs is less clear. ACAs emerging during imatinib treatment may be an independent
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adverse survival factor,7 and patients on imatinib following
interferon failure who developed ACAs are at increased risk of
hematological relapse.8 The significance of certain ACAs
emerging during treatment was confirmed in a 2326-patient
study,9 which identified several adverse ACAs beyond the
original 4 major route lesions. However, the significance of
ACAs already present at initial diagnosis is not as well charac-
terized. In the German/Swiss CML 4 study, the 4 major route
ACAs at diagnosis correlate with poor survival and a sixfold
increased risk of disease progression.10,11 However, this
adverse effect was not confirmed in a study of TKIs in chronic
phase,12 and clonal evolution did not alter overall and event-free
survival (EFS) in second-generation TKI recipients.13 The CML 4
study identified 5 additional lesions (trisomy 21, 3q26.2, mono-
somy 7/7q2, 11q23, and complex karyotypes) beyond the 4
major route lesions, which also confer an increased risk of death
from CML.14 Current European LeukemiaNet recommendations
suggest that any of these 9 lesions should be regarded as
increasing the risk of disease progression,15 and the National
Comprehensive Cancer Network guidelines also recommend
close follow-up of patients with ACAs.16 However, only ;3% of
patients have ACAs at diagnosis, and further studies are needed
to confirm the predictive value of ACAs and their independence
from other progression risk factors.
Several scores derived from simple demographic and diagnostic
data can predict survival,17-19 including the European Treatment
and Outcome Study long-term survival (ELTS) score, derived
from a large TKI-treated population and examining parameters
associated with death from CML, and validated in several large
independent cohorts.20-22
Here, we present details of diagnostic ACAs and their significance
in the recent SPIRIT2 study, focusing on the 9 lesions described
above, and correlate these with the Sokal and ELTS scores.
Patients and methods
The SPIRIT2 clinical trial recruited 814 newly diagnosed patients
with chronic-phase CML between 2008 and 2013 across 146
United Kingdom (UK) sites (www.clinicaltrials.gov; study identifier
#NCT01460693). It was approved by the National Research Ethics
Committee (London Central Office) and the UK Medicines and
Healthcare Products Regulatory Agency. Informed consent was
obtained from patients prior to their inclusion. The study was
sponsored by Newcastle Hospitals National Health Service (NHS)
Trust.
Patients were randomized 1:1 to either dasatinib 100 mg or imatinib
400 mg, each once daily, and followed up monthly for 3 months,
every 3 months until 12 months, and then every 6 months until
5 years or therapy change due to either intolerance or resistance, as
described elsewhere.23 On each occasion, the BCR-ABL1:ABL1
ratio was assessed centrally (Imperial College Healthcare NHS
Trust). The primary end point was 5-year EFS.
On entry, marrow cytogenetics with G-banding were carried out.
Since recording the components of the various prognostic scoring
systems was not mandatory at trial entry, 308 of the 763 patients
with available diagnostic cytogenetics could not be allocated Sokal
or ELTS scores.
Definitions of outcome end points
Progression-free survival (PFS) was defined as the time from trial
entry to disease progression to either accelerated phase or blast
crisis or death from any cause, whichever was earlier. Freedom from
progression (FFP) was defined as the time from entry to pro-
gression alone. Times from entry to molecular response (MR) end
points MR2 (,1% BCR-ABL1), MR3 (,0.1% BCR-ABL1), MR4
(,0.01% BCR-ABL1). and MR4.5 (,0.0032% BCR-ABL1) were
also examined.
Statistical analysis
Survival analysis was performed for PFS, FFP, and time to molecular
end points. Survival distributions were estimated using the Kaplan-
Meier method and compared between the subgroups of interest
with the log-rank test. Cox proportional hazard regression was used
to explore the prognostic factors in both univariable and multivari-
able settings, where backward selection based on the Akaike
information criterion was used for selecting the best model.24 The
Cox models results are presented as hazard ratios (HRs) with 95%
confidence intervals (CIs) alongside the coefficient estimate with its
standard error. The proportional hazard assumption was assessed
via the Schoenfeld residuals.25 Patients with ACAs and progression
were summarized as frequencies of counts and percentages and
compared using Fisher’s exact test. Associations between Sokal or
ELTS scores and ACAs were explored with Fisher’s exact or
Wilcoxon-Mann-Whitney tests. A 5% significance level was used to
determine statistical significance. All analyses were performed using
R version 3.5.1 and STATA v.15 (StatCorp, College Station, TX).
Results
SPIRIT2 recruited 814 patients, but 2 never received their allocated
drug (1 incorrect diagnosis, 1 consent withdrawal) and are
excluded. Table 1 presents diagnostic cytogenetic data for 812
patients, with rates of disease progression. Overall, 23 patients
progressed (12 received dasatinib and 11 imatinib). Diagnostic
cytogenetics were unavailable in 49 patients (1 with progression
and 48 without progression). Of 763 patients with cytogenetic data,
640 had a single t(9;22) Ph translocation only, and 15 (2.3%)
of these patients progressed. Fifty-five patients (one of whom
progressed) had a 3-way variant Ph translocation, and 5 patients
had a 4-way variant Ph (one of whom also had a 3-way Ph variant).
Seventeen of 467 male patients with available diagnostic cytoge-
netics had Y chromosome loss; none of these patients progressed.
Although trial entry required Ph positivity, 6 cytogenetically normal
(but BCR-ABL1-positive) patients were inadvertently recruited;
none of these patients progressed.
Table 1 provides details of the observed ACAs. Seventeen patients
had $1 of the 4 major route lesions described above (2 patients
had 2 such lesions each, detailed in the legend to Table 1), and of
these, 3 patients (17.6%) progressed. Similarly, 14 patients had$1
of the 5 additional lesions described by Hehlmann et al,14 of whom
5 (35.7%) progressed. These are hereafter labeled the “original
major route” and the “additional lesions” groups.
Effect of ACAs on progression and time to MR
Of the 736 patients without any of the 9 original major route or
additional lesion ACAs, 16 (2.2%) progressed. Table 2 shows
that progression is higher with original major route lesions
(17.6%; P 5 .011), with additional lesions (35.7%; P , .001), and
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in the 27 patients with $1 of the 9 lesions (22.2%; P , .001). In
the 6 patients with $1 of these 9 ACAs who progressed, 3 had
received imatinib and 3 dasatinib.
Figure 1 shows the 5-year PFS for patients with an original major
route lesion is 67% (95% CI, 38-85), which is significantly worse
than the 91% (95% CI, 89-93; P , .001) in patients without such
lesions (Figure 1A). Figure 1B-C gives similar results for additional
lesions (60% [32-80] vs 91% [89-93]) and these groups combined
(68% [46-83] vs 92% [89-93]). Median survival was not reached in
any ACA group. However, the 71 PFS events are dominated by the
49 deaths without progression, from causes unrelated to CML.
Figure 2 therefore shows the FFP, in which the only event is
progression, stratified as for Figure 1. Each panel again shows that
ACAs confer significantly worse FFP (80% [51-93] vs 97% [96-98]
for original major route lesions [Figure 2A], 66% [36-84] vs 97%
[96-99] for additional lesions [Figure 2B], and 76% [54-88] vs 98%
[96-99] for these groups combined [Figure 2C]). Original major
route lesions, additional lesions, or these combined had no effect on
the time to MR2, MR3, MR4, or MR4.5 (data not shown).
ACAs do not correlate with Sokal or ELTS score
Sokal and ELTS scores were available in 455 of the 763 patients
with diagnostic cytogenetics. Of these, 167 patients had low, 168
had intermediate, and 120 had high Sokal scores. Supplemental
Figure 1A shows a significant difference in the PFS among these 3
groups, though no difference was seen in FFP (data not shown).
However, no association was seen between the presence/absence
at diagnosis of original major route lesions, additional lesions, or
these combined and the Sokal score when expressed either as
categorical variables (low/intermediate/high; Fisher’s exact test) or
as a continuous variable (Wilcoxon-Mann-Whitney test). Similarly,
252 patients had low, 137 had intermediate, and 66 had high ELTS
scores, and there is a significant difference in both the PFS
(supplemental Figure 1B) and FFP (data not shown) among these
risk groups. However, again, no association was seen between the
presence/absence of original major route lesions, additional lesions,
or these combined and the ELTS score expressed either as
categorical or continuous variable (Wilcoxon-Mann-Whitney test).
Both ACAs and Sokal/ELTS scores independently
predict PFS
Although no association was seen between Sokal or ELTS scores
and either original major route or additional lesion ACAs (or these
combined), the ability of each of these to independently predict PFS
was tested by univariate Cox regression. Table 3 shows that all 5
variables were predictive of PFS. They were then examined in
multivariable models using ACAs summarized as combined lesions
to maximize occurrences and thus provide more accurate estimates
than separate ACA groups. The results for the models are given in
Table 3 (using combined lesions and Sokal score as covariates and
combined lesions and ELTS score). In both cases, the model
including the lesions and the score was selected as best model,
indicating that both the Sokal/ELTS score and combined lesions
are independent predictive factors of PFS.
ACAs and the ELTS score, but not the Sokal score,
predict FFP
The predictive value of the scores and ACAs on FFP is given in
Table 4, which shows that in univariate analysis, the Sokal score
was not predictive of FFP, but original major route lesions, additional
lesions, and these combined were all related to poorer FFP, and
high ELTS scores were associated with inferior FFP when com-
pared with low ELTS scores. In multivariable models, adding the
Sokal score did not improve the predictive value of combined
Table 1. Diagnostic karyotypic data for 812 assessable patients






Normal (no Ph) 6 0
Ph only 625 15 2.3
3-way Ph* 54 1 1.9
4-way Ph* 5 0
Loss of Y 17 0
Original major route lesion 14 3 17.6
Trisomy 8 5† 2‡
Additional Ph 3 1‡
Isochromosome 17q 6 1
Trisomy 19 1† 0
Additional lesions 9 5 35.7
Trisomy 21 0 0
3q26.2 lesion 0 1
Monosomy 7/7q2 2§ 0
11q23 lesion 2 1
Complex karyotype 7§ 3§
Other lesion 20 0
Total unique patients† 741 22 2.9
Karyotype unavailable 48 1 2.0
Two patients of the original 814 who never received trial drug are excluded.
*One patient had both a 3-way and a 4-way Ph translocation.
†One nonprogressing patient had both trisomy 8 and trisomy 19.
‡One progressing patient had both trisomy 8 and a second Ph translocation.
§Of patients with complex karyotypes, 2 nonprogressing patients also had monosomy 7
(one of whom also had isochromosome 17q); furthermore, 1 patient without progression
had trisomy 8 and 19, and 2 progressing patients also had trisomy 8 (one of whom had
a second Ph translocation as well).







Original major route lesion
Yes 14 3 17.6 .011
No 727 19 2.5
Additional lesions
Yes 9 5 35.7 ,.001
No 732 17 2.3
Combined group
Yes 21 6 22.2 ,.001
No 720 16 2.2
Original major route and additional lesions groups are as defined in Table 1 and the text.
The combined group comprises patients with $1 of any of the 9 lesions in either the original
major route or the additional lesions group. P values were evaluated by Fisher’s exact test.
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Figure 1. Patient PFS. Stratified by presence/absence of original major route
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Figure 2. Patient FFP. Stratified by presence/absence of original major route
ACAs (A), additional lesions (B), and combined 9 lesions (C).




 http://ashpublications.org/bloodadvances/article-pdf/5/4/1102/1800704/advancesadv2020003570.pdf by guest on 01 M
arch 2021
lesions, but both the ELTS score and combined lesions were
independent predictive factors for FFP.
Discussion
Data from the German/Swiss CML 4 trial suggest that certain ACAs
at diagnosis might identify patients at high risk of progression.
Additional data on this are needed from large trials. The present
data from the recent 814-patient UK SPIRIT2 study may therefore
be helpful. The progression rate at the end of follow-up in the 27
patients with$1 of the 9 lesions identified in CML 410,11,14 is;10-
fold higher, at 22.2%, and PFS is significantly worse than in patients
without these lesions. This finding is broadly similar to CML 4 and
supports the notion that the 9 ACAs reported in CML 4 represent
a group of adverse ACAs. Although 20 further patients (listed as
“other” in Table 1) had an additional cytogenetic lesion beyond Ph,
these additional lesions were all unique (except for 47 XYY in 2 of
the 467 male cases; this is typically constitutional, but this was not
investigated here). We cannot therefore determine whether further
ACAs might also confer useful information about outcome, despite
the size of the present study. Meta-analyses across several studies
will be needed to address this question.
Secondly, the presence of ACAs is not correlated with the Sokal or
ELTS score, suggesting that ACAs may give additional information
beyond simple demographic and diagnostic hematological data.
Multivariable models confirm that for predicting progression, a high
ELTS score (though not the Sokal score) may add to the value of
ACAs. A composite score combining ACAs with ELTS score might
give a more powerful prediction of progression, but we cannot
determine this, because despite 812 assessable entrants, there
were only 22 progressions with a diagnostic karyotype.
As there are more than twice as many non-CML deaths as progressions
(49 vs 22), we have also reanalyzed the FFP data using non-CML
death as a competing risk. The statistically significant differences for
the cumulative incidence of progression remain unchanged for the
original 4 major route lesions, the 5 additional lesions, and the
combined 9 ACAs. Similarly, the univariate analyses are unchanged,
and furthermore, the multivariable modeling produces the same
findings, namely that in the model including “combined” ACAs and
Sokal score, only the combined ACA was predictive of progression,
but in the model including combined ACAs and ELTS score, both
the ACA and the ELTS score were statistically significant predictors.
The emergence of ACA in Ph-negative cells (ie, clonal cytogenetic
evolution) may occasionally occur during TKI treatment.26-31 The
most common abnormalities include trisomy 8 and loss of the Y
chromosome. In the initial version of the SPIRIT2 protocol, repeat
Table 3. Cox regression examining the effect of scoring systems and ACAs on predicting PFS
Covariate Score levels Estimate (SE) HR (95% CI) P
Univariate analysis
Sokal score Low Reference Reference
Intermediate 0.91 (0.418) 2.49 (1.091, 5.624) .03
High 0.99 (0.438) 2.68 (1.137, 6.325) .024
ELTS score Low Reference Reference
Intermediate 1.15 (0.383) 3.15 (1.488, 6.676) .003
High 1.63 (0.403) 5.11 (2.32, 11.276) ,.001
Original major route lesions No lesions Reference Reference —
Lesions 1.8 (0.526) 6.03 (2.149, 16.9) .001
Additional lesions No lesions Reference Reference —
Lesions 1.57 (0.526) 4.85 (1.711, 13.449) .003
Combined group No lesions Reference Reference —
Lesions 1.61 (0.441) 5.0 (2.106, 11.872) ,.001
Multivariable Cox regression model (Sokal score)
Combined lesions No lesions Reference Reference —
Lesions 1.55 (0.442) 4.73 (1.989, 11.252) ,.001
Sokal score Low Reference Reference —
Intermediate 0.86 (0.419) 2.37 (1.044, 5.395) .039
High 0.96 (0.438) 2.62 (1.1, 6.18) .028
Multivariable Cox regression model (ELTS score)
Combined lesions No lesions Reference Reference —
Lesions 1.48 (0.443) 4.37 (1.836, 10.427) .001
ELTS score Low Reference Reference —
Intermediate 1.09 (0.384) 2.99 (1.408, 6.342) .004
High 1.59 (0.404) 4.92 (2.23, 10.868) ,.001
SE, standard error.
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marrow cytogenetics were requested at 12 and 24 months, but
these proved unpopular in patients with adequate MRs, similar to
other contemporary studies, and were abandoned midtrial in
a protocol revision. We cannot therefore comment on the evolution
of the ACA identified here or on the acquisition of new ACAs that
were absent at initial diagnosis andmay be an unfavorable feature.9,32
However, in the 47 patients with a chromosomal abnormality beyond
Ph at diagnosis (27 with $1 of the 9 ACAs of interest and 20 with
a different lesion), all their lesions were in Ph-positive cells.
Finally, only 23 of the 812 assessable patients progressed (of
whom 12 received dasatinib and 11 imatinib; 1 patient had
missing cytogenetics), a happy consequence of successful
modern TKI therapy. Despite the statistically significant find-
ings, there are only 6 unique patients with $1 of the 9 ACAs of
interest who progressed. In exploratory analysis, if only 5 unique
cases progressed, the significance of the findings would not
change. Nevertheless, we advise caution in overinterpreting the
data. In defining the significance of ACAs, it is unlikely that
a single study or national group will be able to avoid this same
problem, though a meta-analysis with other large studies would
be of considerable interest.
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